

Jacques De Greve

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3539302/jacques-de-greve-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

20,709
citations

40
h-index

143
g-index

170
ext. papers

23,715
ext. citations

4.7
avg, IF

5.57
L-index

#	Paper	IF	Citations
153	Abstract P3-02-05: Assessment of repeatability and uptake quantification of 68GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-02-05-P3-02-05	10.1	
152	Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , 2021 ,	21.7	22
151	Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth.. <i>Frontiers in Immunology</i> , 2021 , 12, 772555	8.4	
150	Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 272-283	4	6
149	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , 2020 , 38, 1096-1107	4.3	3
148	The genomic landscape of nonsmall cell lung carcinoma in never smokers. <i>International Journal of Cancer</i> , 2020 , 146, 3207-3218	7.5	12
147	USP13 controls the stability of Aurora B impacting progression through the cell cycle. <i>Oncogene</i> , 2020 , 39, 6009-6023	9.2	7
146	Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2020 , 148, 2579	7.5	4
145	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 607-615	4.4	4
144	Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer. <i>Breast Journal</i> , 2019 , 25, 663-666	1.2	2
143	Unidentified cachexia patients in the oncologic setting: Cachexia UFOs do exist. <i>Nutrition</i> , 2019 , 63-64, 200-204	4.8	7
142	Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. <i>BMC Cancer</i> , 2019 , 19, 313	4.8	20
141	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019 , 30, 766-773	10.3	46
140	CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. <i>Oncogene</i> , 2019 , 38, 5933-5941	9.2	6
139	Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer. <i>Breast Journal</i> , 2018 , 24, 695-697	1.2	1
138	Therapeutic potential of the vagus nerve in cancer. <i>Immunology Letters</i> , 2018 , 202, 38-43	4.1	22
137	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018 , 132, 391-391	2.2	25

136	Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. <i>Oncotarget</i> , 2018 , 9, 16110-16123	3.3	13
135	The prognostic value of 3 commonly measured blood parameters and geriatric assessment to predict overall survival in addition to clinical information in older patients with cancer. <i>Cancer</i> , 2018 , 124, 3764-3775	6.4	6
134	The added value of geriatric screening and assessment for predicting overall survival in older patients with cancer. <i>Cancer</i> , 2018 , 124, 3753-3763	6.4	20
133	Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector. <i>BMC Research Notes</i> , 2018 , 11, 751	2.3	6
132	Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. <i>Advances in Therapy</i> , 2018 , 35, 1945-1964	4.1	5
131	Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 196-205	3.6	56
130	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. <i>Oncotarget</i> , 2017 , 8, 60094-60108	3.3	67
129	Breast cancer risk is increased in the years following false-positive breast cancer screening. <i>European Journal of Cancer Prevention</i> , 2017 , 26, 396-403	2	4
128	Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e221-e229	3.8	15
127	An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5504-5504	2.2	67
126	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6025-6025	2.2	16
125	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 47154-47160	3.3	18
124	A lung cancer-derived CRAF mutation to activate ERK pathway and to predict sensitivity to LY3009120 and trametinib.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23197-e23197	2.2	
123	Targeting polo-like kinase 1 and TRAIL to enhance apoptosis in non-small cell lung cancer (NSCLC) cells.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14104-e14104	2.2	
122	Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23154-e23154	2.2	
121	Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 27-33	8.9	226
120	The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. <i>Familial Cancer</i> , 2016 , 15, 155-62	3	30
119	The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 143-143	2.2	1

118	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). <i>PLoS ONE</i> , 2016 , 11, e0147599	3.7	17
117	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. <i>Oncotarget</i> , 2016 , 7, 3068-83	3.3	17
116	Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 247-247	2.2	
115	Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients. <i>Clinical Genetics</i> , 2016 , 89, 336-40	4	17
114	Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. <i>Cell Death and Disease</i> , 2016 , 7, e2560	9.8	13
113	Nutrition therapy in cachectic cancer patients. The Tight Caloric Control (TiCaCo) pilot trial. <i>Appetite</i> , 2015 , 91, 298-301	4.5	42
112	Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015 , 23, 163-71	1.9	11
111	Mutanome Engineered RNA Immunotherapy (MERIT). <i>Human Gene Therapy Clinical Development</i> , 2015 , 26, 84-6	3.2	1
110	Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. <i>Lung Cancer</i> , 2015 , 90, 167-74	5.9	8
109	Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 723-9	3.5	35
108	Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer. <i>Oncogene</i> , 2015 , 34, 1650-7	9.2	5
107	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. <i>Lung Cancer</i> , 2015 , 88, 63-9	5.9	60
106	First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5537-5537 ^{2,2}	2.2	8
105	What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5546-5546	2.2	1
104	Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. <i>Oncotarget</i> , 2015 , 6, 20132-44	3.3	7
103	Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11600-e11600	2.2	
102	Quantifying independent risk factors for failing to rescreen in a breast cancer screening program in Flanders, Belgium. <i>Preventive Medicine</i> , 2014 , 69, 280-6	4.3	10
101	Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 673-81	4.4	29

100	How to monitor cardiac toxicity of chemotherapy: time is muscle!. <i>Heart</i> , 2014 , 100, 1208-17	5.1	8
99	Performance of two geriatric screening tools in older patients with cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 19-26	2.2	227
98	Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. <i>Clinical Genetics</i> , 2014 , 85, 59-63	4	13
97	Characterization of ovarian cancer long-term responders on olaparib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5534-5534	2.2	1
96	Impact of an interventional counseling procedure in BRCA families: Efficacy and safety.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1552-1552	2.2	
95	Frequent BRCA1/2 and BARD1 germline mutations in triple-negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1107-1107	2.2	
94	Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. <i>Anticancer Research</i> , 2014 , 34, 5517-21	2.3	40
93	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. <i>Clinical Cancer Research</i> , 2013 , 19, 5485-93	12.9	103
92	Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. <i>Biochemical and Biophysical Research Communications</i> , 2013 , 431, 623-9	3.4	33
91	The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2013 , 4, 235-41	3.6	58
90	Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example. <i>Human Mutation</i> , 2013 , 34, 785-91	4.7	12
89	Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). <i>Journal of Chemotherapy</i> , 2013 , 25, 239-46	2.3	3
88	The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. <i>Oncology Reports</i> , 2013 , 30, 2435-41	3.5	36
87	Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. <i>PLoS ONE</i> , 2013 , 8, e59708	3.7	42
86	miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. <i>PLoS ONE</i> , 2013 , 8, e60317	3.7	207
85	A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1149-59	4.4	59
84	An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012 , 48, 324-32	7.5	70
83	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. <i>BMC Medicine</i> , 2012 , 10, 28	11.4	96

82	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. <i>Lung Cancer</i> , 2012 , 76, 123-7	5.9	213
81	Savene [®] (dexrazoxane) use in clinical practice. <i>Supportive Care in Cancer</i> , 2012 , 20, 1109-12	3.9	22
80	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. <i>International Journal of Oncology</i> , 2012 , 41, 1029-35	4.4	42
79	The effect of a varied exercise program (VEP) on shoulder function and lymphedema (LE) in breast cancer survivors (BCs): A pilot study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 82-82	2.2	1
78	Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2012 , 1, 152-4	4.4	1
77	The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9035-9035	2.2	
76	BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. <i>Neoplasma</i> , 2011 , 58, 198-204	3.3	3
75	Evaluation of a comprehensive rehabilitation program for post-treatment patients with cancer. <i>Oncology Nursing Forum</i> , 2011 , 38, E418-24	1.7	16
74	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 671-9	4.4	21
73	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 491-501	4.8	99
72	The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. <i>BMC Medical Genetics</i> , 2011 , 12, 9	2.1	22
71	Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. <i>Gynecologic and Obstetric Investigation</i> , 2011 , 71, 141-4	2.5	22
70	Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. <i>Gastrointestinal Cancer Research: GCR</i> , 2011 , 4, 40-4		38
69	Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. <i>Anticancer Research</i> , 2011 , 31, 1407-9	2.3	23
68	Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. <i>Anticancer Research</i> , 2011 , 31, 4457-63	2.3	24
67	Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. <i>Biological Procedures Online</i> , 2010 , 13, 1	8.3	32
66	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2512-9	2.2	737
65	406 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease. <i>European Journal of Cancer, Supplement</i> , 2010 , 8, 129	1.6	3

64	Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer</i> , 2010 , 46, 2206-15	7.5	78
63	Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. <i>Cancer</i> , 2010 , 116, 241-50	6.4	16
62	Individual cancer risk as a function of current age and risk profile. <i>European Journal of Cancer Prevention</i> , 2010 , 19, 485-95	2	6
61	A community peer-volunteer telephone reminder call to increase breast cancer-screening attendance. <i>Oncology Nursing Forum</i> , 2010 , 37, E312-7	1.7	11
60	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 463-9	4.4	39
59	Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. <i>Human Mutation</i> , 2010 , 31, E1175-85	4.7	67
58	Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. <i>Analytical Biochemistry</i> , 2010 , 398, 266-8	3.1	22
57	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. <i>Annals of Oncology</i> , 2009 , 20, 1596-1603	10.3	166
56	About the c.156_157insAlu BRCA2 breast cancer predisposing mutation. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 621-2	4.4	2
55	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. <i>European Journal of Cancer</i> , 2009 , 45, 146-53	7.5	44
54	Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2009 , 4, 728-35	8.9	9
53	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. <i>BMC Cancer</i> , 2008 , 8, 3	4.8	46
52	Tolerance of adjuvant letrozole outside of clinical trials. <i>Breast</i> , 2008 , 17, 376-81	3.6	45
51	Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008 , 62, 55-61	5.9	53
50	The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. <i>European Journal of Cancer</i> , 2008 , 44, 84-91	7.5	133
49	Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results. <i>Radiology</i> , 2008 , 249, 471-82	20.5	46
48	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. <i>Annals of Oncology</i> , 2008 , 19, 920-6	10.3	119
47	BRCA2 gene mutations in Slovenian male breast cancer patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2008 , 12, 203-9		14

46	Hereditary breast cancer: from bench to bedside. <i>Current Opinion in Oncology</i> , 2008 , 20, 605-13	4.2	18
45	Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 59-65	4.4	19
44	Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. <i>BMC Medical Genetics</i> , 2008 , 9, 83	2.1	29
43	Phase II study of preoperative helical tomotherapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 728-34	4	58
42	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2007 , 56, 247-54	5.9	8
41	Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007 , 619, 104-12	3.3	5
40	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. <i>European Respiratory Journal</i> , 2007 , 29, 128-33	13.6	11
39	A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 3652-9	12.9	24
38	Metastatic adenocarcinoma of the lung in a 27-year-old pregnant woman. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 450-2	8.9	6
37	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4293-300	2.2	1002
36	Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. <i>Anticancer Research</i> , 2006 , 26, 611-9	2.3	15
35	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>New England Journal of Medicine</i> , 2005 , 352, 987-96	59.2	13703
34	De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. <i>Human Mutation</i> , 2005 , 26, 284	4.7	68
33	Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. <i>Supportive Care in Cancer</i> , 2005 , 13, 325-31	3.9	135
32	Paraneoplastic syndromes in cancer: Case 1. Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2240-2	2.2	23
31	Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. <i>Annals of Oncology</i> , 2004 , 15, 59-63	10.3	38
30	The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation. <i>Journal of Medical Genetics</i> , 2004 , 41, e23	5.8	49
29	Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. <i>Cancer Detection and Prevention</i> , 2003 , 27, 380-8		

28	High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. <i>European Journal of Cancer</i> , 2003 , 39, 346-52	7.5	5
27	Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 274-9	5.1	18
26	BRCA2 founder mutation in Slovenian breast cancer families. <i>European Journal of Human Genetics</i> , 2002 , 10, 879-82	5.3	18
25	Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1750-8	2.2	189
24	Characterization of permanent cell lines that contain the AAV2 rep-cap genes on an Epstein-Barr-virus-based episomal plasmid. <i>Intervirolology</i> , 2001 , 44, 255-63	2.5	2
23	Contaminants within bacterial plasmid preparations trigger apoptosis in liposome transfected OVCAR3, but not in SKOV3 or AZ224 human ovarian cancer cells. <i>Cell Biology International</i> , 2001 , 25, 715-23	4.5	5
22	Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. <i>British Journal of Cancer</i> , 2001 , 85, 1592-9	8.7	13
21	Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. <i>British Journal of Cancer</i> , 2001 , 85, 1-8	8.7	24
20	Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1595-600	2.2	25
19	BRCA 1/2 gene mutation testing-based cancer prevention and the moral concerns of different types of patients. <i>Annals of the New York Academy of Sciences</i> , 1999 , 889, 240-3	6.5	3
18	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. <i>International Journal of Cancer</i> , 1999 , 80, 219-30	7.5	587
17	Alteration of jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells. <i>International Journal of Cancer</i> , 1999 , 82, 687-93	7.5	13
16	Pharmacokinetics of intravenous alendronate. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 385-93	2.9	41
15	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 1999 , 80, 219		12
14	Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. <i>Journal of Clinical Oncology</i> , 1998 , 16, 411-7	2.2	114
13	Ethical aspects of genetic counseling in familial breast and ovarian cancer. Combining applied theory and reflective practice. <i>Annals of the New York Academy of Sciences</i> , 1997 , 833, 170-2	6.5	1
12	. <i>Annals of Oncology</i> , 1997 , 8, 691-694	10.3	9
11	Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). <i>European Journal of Cancer</i> , 1996 , 32A, 1432-3	7.5	2

10	Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1996 , 429, 59-68	5.1	22
9	A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. <i>European Journal of Cancer</i> , 1995 , 31A, 2157-63	7.5	14
8	Non-small-cell lung cancer with multiple paraneoplastic syndromes. <i>European Respiratory Journal</i> , 1995 , 8, 1231-4	13.6	16
7	Tumour stimulating effects of recombinant human interleukin-6. <i>Lancet, The</i> , 1994 , 344, 1576-7	40	29
6	Imaging of renal cell cancer with radiolabelled octreotide. <i>Nuclear Medicine Communications</i> , 1993 , 14, 873-7	1.6	18
5	Is adjuvant treatment with vinblastine effective in reducing the occurrence of distant metastasis in limited squamous cell lung cancer? A randomized study. <i>Clinical and Experimental Metastasis</i> , 1988 , 6, 39-48	4.7	9
4	Unusual nonimmunoglobulin-containing inclusions in a case of follicular large cell lymphoma. <i>Ultrastructural Pathology</i> , 1985 , 8, 71-82	1.3	
3	Fatal pulmonary toxicity by the association of radiotherapy and medroxyprogesterone acetate. <i>Cancer</i> , 1985 , 56, 2434-6	6.4	10
2	Lower motor neuron disease in a patient with Hodgkin's disease treated with radiotherapy. <i>Clinical Neurology and Neurosurgery</i> , 1984 , 86, 43-6	2	10
1	Osteopathia striata with cranial sclerosis. Report of a case and review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 1983 , 85, 41-8	2	20